Direct 20S proteasome activation restores proteostasis
PrimaryBooster Therapeutics' central causal theory is that small molecules can directly activate the 20S proteasome, boosting the cell's endogenous protein quality-control machinery. Increased 20S proteasome activity is expected to restore impaired proteasome function, enhance clearance of disease-causing or aggregation-prone proteins, and rebalance cellular homeostasis. Testable predictions include increased proteasome activity in biochemical and cellular assays after treatment, reduced accumulation of aggregation-prone proteins, improved degradation of intrinsically disordered proteins, and downstream correction of proteostasis defects in age-related or neurodegenerative disease models.
Popperian evaluation
The starting premise is credible: 20S proteasome activation by small molecules has direct biochemical and cellular support from AM404 analogs A22 and A23. The causal chain becomes less secure when it moves from enzyme activation to disease-relevant proteostasis repair. That jump depends on selectivity, exposure, tolerability, and whether proteasome dysfunction is a driver rather than a bystander in the target diseases.
Supporting evidence: AM404 analogs A22 and A23 increased proteasome activity in biochemical assays.; A22 and A23 increased proteasome activity in cellular assays.; The same compounds degraded intrinsically disordered proteins and restored proteasome activity in the presence of toxic oligomeric alpha-synuclein species in a biochemical setting.
Counter evidence: The evidence context does not show correction of disease phenotypes in age-related or neurodegenerative models.; The theory requires enough selectivity and tolerability to avoid harmful excess protein degradation, and that condition remains an assumption here.
The theory explains the reported assay results fairly well because the observations line up with the proposed mechanism: direct 20S activation, improved proteasome activity, and degradation of intrinsically disordered proteins. It does not yet beat alternative explanations decisively. The same readouts could reflect assay-specific effects, altered substrate access, compound-specific chemistry, or stress-response changes rather than a general restoration of proteostasis.
Supporting evidence: The predicted increase in biochemical proteasome activity was observed with A22 and A23.; The predicted increase in cellular proteasome activity was observed with A22 and A23.; The prediction about degradation of intrinsically disordered proteins has direct support from the reported assays.
Counter evidence: Restoration in the presence of oligomeric alpha-synuclein was shown in a biochemical setting, which does not prove correction inside diseased neurons or aged tissue.; The evidence context does not report competing-mechanism controls strong enough to rule out non-20S explanations for all downstream effects.
The theory is easy to put at risk. It predicts measurable increases in 20S activity, reduced accumulation of aggregation-prone proteins, improved degradation of intrinsically disordered proteins, and correction of proteostasis defects in disease models. A clean failure in cells or animal disease models, especially with target-engagement controls showing the compound reaches the proteasome, would damage the theory rather than merely inconvenience it.
Supporting evidence: The theory names biochemical proteasome activity as a direct testable readout.; The theory names cellular proteasome activity as a direct testable readout.; The theory predicts reduced aggregation-prone protein accumulation and downstream correction of proteostasis defects in age-related or neurodegenerative disease models.
Counter evidence: Some predictions remain broad, especially 'rebalance cellular homeostasis', unless tied to predefined quantitative endpoints.; The disease-model prediction is present but not yet backed by evidence in the supplied context.
Reasoning tree
Public endorsements
The provided evidence does not show Aldemar Degroot STRATEGIC making any public statement about Booster Therapeutics or its 20S proteasome activation theory. One record appears unrelated to the company, and the Booster launch article quotes a different person.
The record set identifies Dr. Diogo R. Feleciano as Booster Therapeutics' co-founder and CSO, and the company materials describe a 20S proteasome activator strategy. But there is no direct public quote or attributed statement from him in the provided evidence that explicitly endorses, explains, or disputes the theory. On this dossier, he is publicly associated with the company, but silent on the theory itself.
Evidence publication IDs: 50635ef8-ea40-4775-a122-33f5e7c04f2f, a13b9514-dc46-450b-9353-afdb74cf69b4, 1d68a2a8-ebb1-4d77-9835-789d2da6ee2c
The evidence shows Diogo R. Feleciano is Booster Therapeutics' Co-Founder and CSO, but the provided quotes and records do not contain a public statement from him endorsing, describing, or disputing the specific theory that direct 20S proteasome activation restores proteostasis. The launch coverage mentions proteasome activators, but the excerpted theory-facing quote is not attributed to him.
Feleciano is not a distant observer here, he is Booster Therapeutics' co-founder and CSO. He is also listed as the author of Booster's launch press release, which presents the company as developing a new class of proteasome activator medicines. That is a public endorsement of the core theory that activating the proteasome can produce therapeutic benefit.
Evidence publication IDs: bab8854d-a1af-4a67-a2dc-f6f4fc16355c